论文部分内容阅读
试用广东省首次自己合成的羟基脲治疗5例慢性粒细胞白血病(简称慢粒),剂量30～46毫克/公斤体重/日口服,均获得满意疗效。白细胞数均降至正常,幼稚细胞消失,脾脏明显缩小,症状明显好转。无明显副作用,易为患者接受。其中两例早期急变病例,疗效亦满意。因此,认为本药为治疗本病安全有效药物,其疗效与马利兰相近。本药对急变病例亦有效,对抗马利兰的病例仍然有效,为其重要的特点,可补马利兰之不足。但本药不易于维持治疗,因此在病的治疗中,马利兰与羟基脲各有特点,羟基脲尚不能完全取代马利兰的地位。
Trial of the first time in Guangdong Province hydroxyurea synthesis of 5 cases of chronic myeloid leukemia (CML), the dose of 30 to 46 mg / kg body weight / day orally, were satisfactory results. The number of white blood cells were reduced to normal, naive cells disappeared, the spleen was significantly reduced, the symptoms improved significantly. No obvious side effects, easy for patients to accept. Two cases of early acute cases, the effect is also satisfactory. Therefore, that the drug for the treatment of the disease is safe and effective drug, its efficacy and Maryland similar. The drug is also effective in catastrophic cases, the case against Maryland is still valid, for its important features, can make up for the lack of Maryland. However, the drug is not easy to maintain treatment, so the treatment of disease, Maryland and hydroxyurea have their own characteristics, hydroxyurea can not completely replace Maryland’s status.